Application potential of bacterial flagellin in treatment of autoimmune rheumatic diseases with Treg epitope peptides
10.3760/cma.j.issn.0254-5101.2019.09.012
- VernacularTitle: 细菌鞭毛蛋白在Treg表位肽自身免疫性风湿病治疗中的应用前景
- Author:
Mengmeng LI
1
;
Xiao LIU
1
;
Jian YIN
1
;
Zhen WANG
1
;
Yaqun LIU
1
;
Feng QIAN
1
;
Huji XU
1
,
2
Author Information
1. Department of Rheumatology and Immunology, Shanghai Changzheng Hospital, Naval Medical University, Shanghai 200003, China
2. Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing 102218, China
- Publication Type:Review
- Keywords:
Bacterial flagellin;
Treg epitope;
Autoimmune rheumatic disease;
Conjugate;
Vaccine efficacy
- From:
Chinese Journal of Microbiology and Immunology
2019;39(9):710-714
- CountryChina
- Language:Chinese
-
Abstract:
Immunization with regulatory T cell (Treg) epitope peptides to activate and induce Tregs, by which to suppress pathological autoimmune responses and reconstitute a new homeostasis, is a promising therapeutic regimen for autoimmune rheumatic diseases. However, it is usually hard to induce potent peptide-specific immune responses in vivo with small molecular peptides. Bacterial flagellin is one of the agonists triggering innate immune responses. When used as carrier, it shows strong adjuvant activity to its conjugated antigens. In some particular situations, bacterial flagellin can also activate and induce Tregs. Thus if Treg epitope peptides are covalently conjugated to a bacterial flagellin, the conjugates should be able to effectively enhance the Treg-based immune responses via flagellin itself and the adjuvanticity of flagellin to Treg epitope peptides, and thereby enhance the immunotherapeutic effects on autoimmune rheumatic diseases.
